HBI Deals+Insights / News
CRISPR has been called one of the most exciting developments in genetic engineering. It is opening up new possibilities in medicine, particularly for discovering new types of drugs for genetic diseases and new ways of repairing and replacing organs and tissue in regenerative medicine. In an interview with HBI, Philip Hargreaves, Director of Strategic Marketing & Business Development at Promega UK, the UK branch of US biotech company Promega, spoke about how CRISPR, when combined with Promega’s innovative HiBiT technology, can accelerate the drug discovery process.